NicOx

Nicox S.A. is a French ophthalmology company developing treatments to maintain vision and improve ocular health.[1] Nicox is headquartered in Sophia Antipolis, France, and its Chairman and CEO is Michele Garufi.[2][3]

Nicox S.A.
TypeSociété Anonyme
Euronext: COX
Founded1996 (1996)
Headquarters
Sophia Antipolis
,
France
Websitewww.nicox.com

Nicox is listed on Euronext Paris[4] (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. Its pipeline includes three programs in development and it has two U.S. Food and Drug Administration (FDA) approved products.[5]

Pipeline

Nicox's lead program in clinical development is NCX 470, a novel, second-generation nitric oxide-donating bimatoprost analog, for lowering intraocular pressure (IOP) in patients with glaucoma.[6] NCX 470 is designed to release both bimatoprost, which is marketed under the brand name LUMIGAN, and nitric oxide following instillation into the eye. Bimatoprost is a prostaglandin analog, the most widely used class of drugs for IOP lowering in patients with open angle glaucoma and ocular hypertension.[7][8]

The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis.[9] Nicox generates revenue from VYZULTA(R) in glaucoma and ZERVIATE(TM), or cetirizine ophthalmic solution, in allergic conjunctivitis. It has ongoing partnerships with Bausch & Lomb, Eyevance Pharmaceuticals and Ocumension Therapeutics.[10][11]

References
  1. https://www.bloomberg.com/quote/COX:FP
  2. "Here's a French Biotech Investors May Not Care About Enough". Bloomberg.com. Retrieved 2018-08-08.
  3. https://www.boursier.com/actions/actualites/interviews/michele-garufi-pdg-de-nicox-5146.html
  4. https://live.euronext.com/en/product/equities/FR0013018124-XPAR
  5. https://seekingalpha.com/symbol/NICXF
  6. Clinical trial number NCT03657797 for "Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension" at ClinicalTrials.gov
  7. Sambhara, Deepak; Aref, Ahmad A. (2014). "Glaucoma management: relative value and place in therapy of available drug treatments". Therapeutic Advances in Chronic Disease. 5 (1): 30–43. doi:10.1177/2040622313511286. PMC 3871276. PMID 24381726.
  8. https://www.healio.com/news/optometry/20120225/prostaglandin-analogs-the-gold-standard-for-glaucoma
  9. Clinical trial number NCT03926026 for "Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis" at ClinicalTrials.gov
  10. https://www.bloomberg.com/press-releases/2020-03-31/nicox-nicox-announces-zerviate-launch-by-partner-eyevance-pharmaceuticals-in-the-united-states
  11. https://uk.reuters.com/article/brief-nicox-updates-agreement-with-ocume/brief-nicox-updates-agreement-with-ocumension-therapeutics-on-zerviate-idUKFWN2B4063
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.